Reduced secondary cytokine induction by BAY 50-4798, a high-affinity receptor-specific interleukin-2 analog

Journal of Interferon and Cytokine Research

Volumn 26, Issue 3, 2006, Pages 171-178

  Steppan, Sonja ^a,b,e   Eckart, Michael R ^a,c   Bajsarowicz, Krystyna ^a,d   Sternberg, Lawrence R ^a   Greve, Jeffrey M ^a   Cassell, Delanie J ^a  

^a BAYER CORPORATION   (United States)

^b BAYER PHARMA AG   (Germany)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BAY 504798; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 DERIVATIVE; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENCY; DRUG SAFETY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; NATURAL KILLER T CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR AFFINITY; STATISTICAL ANALYSIS; T LYMPHOCYTE;

CELL PROLIFERATION; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; CONCANAVALIN A; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERLEUKIN-2; KILLER CELLS, NATURAL; KINETICS; LEUKOCYTES, MONONUCLEAR; MITOGENS; RECEPTORS, INTERLEUKIN-2; RECOMBINANT PROTEINS; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

CHIRON; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33645413614     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2006.26.171     Document Type: Article

References (53)

1. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976;193:1007-1008.
2. Mingari MC, Gerosa F, Carra G, Accolla RS, Moretta A, Zubler RH, Waldmann TA, Moretta L. Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells. Nature 1984;312:641-643.
3. Espinoza-Delgado I, Bosco MC, Musso T, Gusella GL, Longo DL, Varesio L. Interleukin-2 and human monocyte activation. J. Leukoc. Biol. 1995;57:13-19.
4. Domzig W, Stadler BM, Herberman RB. Interleukin 2 dependence of human natural killer (NK) cell activity. J. Immunol. 1983;130:1970-1973.
5. Taniguchi T. Structure and function of IL-2 and IL-2 receptors. Behring Inst. Mitt. 1992;91:87-95.
6. Krastev Z, Koltchakov V, Tomov B, Koten JW. Non-melanoma and non-renal cell carcinoma malignancies treated with interleukin-2. Hepatogastroenterology 2003;50:1006-1016.
7. Interleukin-2: SILCAAT study to continue. Proj. Inf. Perspect. 2003;36:14.
8. Dragsted UB, Afzelius P, Nielsen SD, Lundgren JD. [Treatment of HIV infections with antiretroviral drugs and recombinant interleukin-2.] Ugeskr. Laeger 2000;162:5614-5618.
9. Emery S, Abrams DI, Cooper DA, Darbyshire JH, Lane HC, Lundgren JD, Neaton JD. The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control. Clin. Trials. 2002;23:198-220.
10. Pett SL, Emery S. Immunomodulators as adjunctive therapy for HIV-1 infection. J. Clin. Virol. 2001;22:289-295.
11. Davey RT Jr, Chaitt DG, Albert JM, Piscitelli SC, Kovacs JA, Walker RE, Falloon J, Polis MA, Metcalf JA, Masur H, Dewar R, Baseler M, Fyfe G, Giedlin MA. Lane HC. A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J. Infect. Dis. 1999;179:849-858.
12. Kovacs JA, Baseler M, Dewar RJ, Vogel S, Davey RT Jr, Falloon J, Polis MA, Walker RE, Stevens R, Salzman NP, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N. Engl. J. Med. 1995;332:567-575.
13. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 1989;210:474-484; discussion 484-475.
14. Wolbink GJ, Schalkwijk C, Baars JW, Wagstaff J, van den Bosch H, Hack CE. Therapy with interleukin-2 induces the systemic release of phospholipase-A2. Cancer Immunol. Immunother. 1995;41:287-292.
15. Smith KA. Low-dose daily interleukin-2 immunotherapy: accelerating immune restoration and expanding HIV-specific T-cell immunity without toxicity. AIDS 2001;15(Suppl 2):S28-35.
16. Tavel JA, Sereti I, Walker RE, Hahn B, Kovacs JA, Jagannatha S, Davey RT Jr, Falloon J, Polis MA, Masur H, Metcalf JA, Stevens R, Rupert A, Baseler M, Lane HC. A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus. J. Infect. Dis. 2003;188:531-536.
17. Jewett A, Bonavida B. Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells. J. Clin. Immunol. 1995;15:35-44.
18. Numerof RP, Aronson FR, Mier JW. IL-2 stimulates the production of IL-1 alpha and IL-1 beta by human peripheral blood mononuclear cells. J. Immunol. 1988;141:4250-4257.
19. Perussia B. The cytokine profile of resting and activated NK cells. Methods 1996;9:370-378.
20. Yu TK, Caudell EG, Smid C, Grimm EA. IL-2 activation of NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway. J. Immunol. 2000;164:6244-6251.
21. Shanafelt AB, Lin Y, Shanafelt MC, Forte CP, Dubois-Stringfellow N, Carter C, Gibbons JA, Cheng SL, Delaria KA, Fleischer R, Greve JM, Gundel R, Harris K, Kelly R, Koh B, Li Y, Lantz L, Mak P, Neyer L, Plym MJ, Roczniak S, Serban D, Thrift J, Tsuchiyama L, Wetzel M, Wong M, Zolotorev A. A T cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nat. Biotechnol. 2000;18:1197-1202.
22. Buchli PJ, Wu Z, Ciardelli TL. The functional display of interleukin-2 on filamentous phage. Arch. Biochem. Biophys. 1997;339:79-84.
23. Collins L, Tsien WH, Seals C, Hakimi J, Weber D, Bailon P, Hoskings J, Greene WC, Toome V, Ju G. Identification of specific residues of human interleukin 2 that affect binding to the 70-kDa subunit (p70) of the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA 1988;85:7709-7713.
24. Eckenberg R, Xu D, Moreau JL, Bossus M, Mazie JC, Tartar A, Liu XY, Alzari PM, Bertoglio J, Theze J. Analysis of human IL-2/IL-2 receptor beta chain interactions: monoclonal antibody H2-8 and new IL-2 mutants define the critical role of alpha helix-A of IL-2. Cytokine 1997;9:488-498.
25. Xu D, Eckenberg R, Moreau JL, Liu XY, Theze J, Bertoglio J. Biological and receptor-binding activities of human interleukin-2 mutated at residues 20Asp, 125Cys or 127Ser. Eur. Cytokine Netw. 1995;6:237-244.
26. Cassell DJ, Choudhri S, Humphrey R, Martell RE, Reynolds T, Shanafelt AB. Therapeutic enhancement of IL-2 through molecular design. Curr. Pharm. Des. 2002;8:2171-2183.
27. Matthews L, Chapman S, Ramchandani MS, Lane HC, Davey RT Jr, Sereti I. BAY 50-4798, a novel, high-affinity receptor-specific recombinant interleukin-2 analog, induces dose-dependent increases in CD25 expression and proliferation among unstimulated, human peripheral blood mononuclear cells in vitro. Clin. Immunol. 2004;113:248-255.
28. Hladik F, Tratkiewicz JA, Tilg H, Vogel W, Schwulera U, Kranke M, Aulitzky WE, Huber C. Biologic activity of low dosage IL-2 treatment in vivo. Molecular assessment of cytokine network interaction. J. Immunol. 1994;153:1449-1454.
29. Peest D, Leo R, Deicher H. Tumor-directed cytotoxicity in multiple myeloma-the basis for an experimental treatment approach with interleukin 2. Stem Cells 1995;13(Suppl 2):72-76.
30. Gillis S, Ferm MM, Ou W, Smith KA. T cell growth factor: parameters of production and a quantitative microassay for activity. J. Immunol. 1978;120:2027-2032.
31. Wetzel M, et al. BAY 50-4798, an interleukin-2 (IL-2) variant, demonstrates selective activation of human and chimpanzee T cells relative to NK cells but shows less selectivity for T cells from monkeys and rodents. American Society of Clinical Oncology 37th Annual Meeting, May 12-15, 2001, San Francisco, CA, 2001.
32. Hara H, Tanaka T, Negoro S, Deguchi Y, Nishio S, Saiki O, Kishimoto S. Age-related changes of expression of IL-2 receptor subunits and kinetics of IL-2 internalization in T cells after mitogenic stimulation. Mech. Ageing Dev. 1988;45:167-175.
33. June CH, Jackson KM, Ledbetter JA, Leiden JM, Lindsten T, Thompson CB. Two distinct mechanisms of interleukin-2 gene expression in human T lymphocytes. J. Autoimmun. 1989;2(Suppl):55-65.
34. Heaton KM, Ju G, Grimm EA. Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy. Cancer Res. 1993;53:2597-2602.
35. Ben Aribia MH, Moire N, Metivier D, Vaquero C, Lantz O, Olive D, Charpentier B, Senik A. IL-2 receptors on circulating natural killer cells and T lymphocytes. Similarity in number and affinity but difference in transmission of the proliferation signal. J. Immunol. 1989;142:490-499.
36. Wang HM, Smith KA. The interleukin 2 receptor. Functional consequences of its bimolecular structure. J. Exp. Med. 1987;166:1055-1069.
37. Piscitelli SC, Wells MJ, Metcalf JA, Baseler M, Stevens R, Davey RT, Jr. Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 in HIV-infected patients. Pharmacotherapy 1996;16:754-759.
38. Sereti I, Herpin B, Metcalf JA, Stevens R, Baseler MW, Hallahan CW, Kovacs JA, Davey RT, Lane HC. CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients. AIDS 2001;15:1765-1775.
39. Dubinett SM, Huang M, Lichtenstein A, McBride WH, Wang J, Markovitz G, Kelley D, Grody WW, Mintz LE, Dhanani S. Tumor necrosis factor-alpha plays a central role in interleukin-2-induced pulmonary vascular leak and lymphocyte accumulation. Cell. Immunol. 1994;157:170-180.
40. Economou JS, Hoban M, Lee JD, Essner R, Swisher S, McBride W, Hoon DB, Morton DL. Production of tumor necrosis factor alpha and interferon gamma in interleukin-2-treated melanoma patients: correlation with clinical toxicity. Cancer Immunol. Immunother. 1991;34:49-52.
41. Klein SA, Dobmeyer JM, Dobmeyer TS, Falke D, Kabelitz D, Friese K, Helm EB, Hoelzer D, Rossol-Voth R. TNF-alpha mediated apoptosis of CD4 positive T-lymphocytes. A model of T-cell depletion in HIV infected individuals. Eur. J. Med. Res. 1996;1:249-258.
42. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995;377:348-351.
43. Thornton S, Kuhn KA, Finkelman FD, Hirsch R. NK cells secrete high levels of IFN-gamma in response to in vivo administration of IL-2. Eur. J. Immunol. 2001;31:3355-3360.
44. Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA, Ritz J. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J. Exp. Med. 1990;171:1509-1526.
45. Hodge S, Hodge G, Flower R, Han P. Surface and intracellular interleukin-2 receptor expression on various resting and activated populations involved in cell-mediated immunity in human peripheral blood. Scand. J. Immunol. 2000;51:67-72.
46. Frankova D, Zidek Z. IFN-gamma-induced TNF-alpha is a prerequisite for in vitro production of nitric oxide generated in murine peritoneal macrophages by IFN-gamma. Eur. J. Immunol. 1998;28:838-843.
47. Green SJ, Scheller LF, Marietta MA, Seguin MC, Klotz FW, Slayter M, Nelson BJ, Nacy CA. Nitric oxide: cytokine-regulation of nitric oxide in host resistance to intracellular pathogens. Immunol. Lett. 1994;43:87-94.
48. Liew FY. Regulation of nitric oxide synthesis in infectious and autoimmune diseases. Immunol. Lett. 1994;43:95-98.
49. Nacy CA, Meierovics AI, Belosevic M, Green SJ. Tumor necrosis factor-alpha: central regulatory cytokine in the induction of macrophage antimicrobial activities. Pathobiology 1991;59:182-184.
50. Winston BW, Krein PM, Mowat C, Huang Y. Cytokine-induced macrophage differentiation: a tale of 2 genes. Clin. Invest. Med. 1999;22:236-255.
51. Hu P, Mizokami M, Ruoff G, Khawli LA, Epstein AL. Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity. Blood 2003;101:4853-4861.
52. Sereti I, Gea-Banacloche J, Kan MY, Hallahan CW, Lane HC. Interleukin 2 leads to dose-dependent expression of the alpha chain of the IL-2 receptor on CD25-negative T lymphocytes in the absence of exogenous antigenic stimulation. Clin. Immunol. 2000;97:266-276.
53. Matthews L, Chapman S, Ramchandani MS, Lane HC, Davey RT Jr, Seneti I. BAY 50-4798, a novel, high-affinity receptor-specific recombinant interleukin-2 analog, induces dose-dependent increases in CD25 expression and proliferation among unstimulated, human peripheral blood mononuclear cells in vitro. Clin. Immunol. 2004;113:248-255.